

Contact:

Loraine V. Upham

Lori@CureDM.com

(505-515-1947)

CureDM Files Annual Report with the US FDA

Wilmington, DE – October 12, 2017 – CureDM announces filing of Annual Report with the United States Food and Drug Administration (FDA) to continue clinical development of their lead compound, HIP2B. HIP2B is a human-derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets. Both type 1 and type 2 indications are being pursued.

CEO, Loraine Upham explains, “The data from our Phase 1b Study in Type 2 patients provided critical information about the activity of our compound and its potential to treat both type 1 and type 2 diabetes. We are in the process of designing a definitive phase 2 study in type 2 patients, as well as a proof of concept study in a specific population of type 1 patients for whom we think this treatment may be transformative.”

CureDM is actively engaged in fundraising, clinical development planning and partnering to bring forth a novel treatment approach to diabetes with their lead compound, HIP2B.

About CureDM

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit www.curedm.com.

XXXXXX